On an annual basis, sales fell from KRW 148.1 billion in 2022 to KRW 111.6 billion in 2023 (down 24.6% year on year), then rose to KRW 162.4 billion in 2024 (up 45.4%), which was the largest year of 2022 to 2025. Sales were KRW 160.3 billion in 2025 (down 1.3%), and 2023 was the smallest year in that span.
Operating profit was KRW 6.86 billion in 2022, then turned into an operating loss of KRW 22.1 billion in 2023, a swing from profit to loss. The loss continued in 2024 at KRW 16.5 billion, with the loss narrowing.
In 2025 the company returned to operating profit of KRW 6.24 billion, and the operating margin was 3.9%, following 4.6% in 2022, -19.8% in 2023 and -10.2% in 2024.
Net income attributable to controlling shareholders was KRW 79.3 billion in 2023 (up 191.4%), then became a net loss of KRW 51.6 billion in 2024, and returned to profit of KRW 28.4 billion in 2025.
For the 2024 loss, a Korean news report pointed to the fair-value marking of the company's stake in a fund tied to HPSP, which affected the income statement; it described this as a book-value change rather than a realized loss (April 2025 report).
Because operating and net results did not move in the same direction, non-operating items appear to have carried significant weight. Quarterly sales peaked at KRW 51.8 billion in the fourth quarter of 2025, then fell to KRW 36.3 billion in the first quarter of 2026 (down 29.9% from the prior quarter).
After KRW 28.5 billion in the second quarter, sales were KRW 28.2 billion in the third quarter of 2026 with an operating loss of KRW 3.08 billion, a swing into loss, and a widening of the loss versus the year-earlier quarter.
Operating cash flow improved from KRW -14.7 billion in 2023 to KRW 3.08 billion in 2024 and KRW 12.4 billion in 2025. Quarterly net income attributable to controlling shareholders peaked at KRW 18.2 billion in the first quarter of 2026 and declined for two consecutive quarters to KRW 9.35 billion in the third quarter.